drugset / Trial / NCT01287793

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793

Phase 1 Completed 48 enrolled Pfizer
RandomizedCrossoverDouble-blind

Summary

Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.

Timeline

Start
2011-01
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Tigecycline Small molecule 50 mg Intravenous
Subject Tigecycline Small molecule 200 mg Intravenous

Indications

No indication recorded.